Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs
作者:Sarah T. Al-Rashood、Ihsan A. Aboldahab、Mahmoud N. Nagi、Laila A. Abouzeid、Alaa A.M. Abdel-Aziz、Sami G. Abdel-hamide、Khairia M. Youssef、Abdulrahman M. Al-Obaid、Hussein I. El-Subbagh
DOI:10.1016/j.bmc.2006.08.030
日期:2006.12
In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of mammalian DHFR activity. Molecular modeling studies were used to assess the fit of these compounds within the active site of human DHFR. The synthesized compounds were evaluated
为了生产有效的抗癌新药,设计了一系列新的喹唑啉类似物,使其具有类似甲氨蝶呤(MTX,1)的结构特征,并装有被认为可增强对哺乳动物DHFR活性抑制作用的官能团。分子建模研究用于评估这些化合物在人DHFR活性位点内的适合性。在标准的体外组织培养测定组中评价了合成的化合物在体外抑制哺乳动物DHFR的能力和其抗肿瘤活性。化合物28、30和31是最具活性的DHFR抑制剂,IC(50)值分别为0.5、0.4和0.4microM。在这项研究中最活跃的抗肿瘤药是化合物19、31、41和47,其中位生长抑制浓度(GI(50))分别为20.1、23.5、26.7和9.1microM。在这一系列化合物中,只有化合物31结合了抗肿瘤潜能和有效的DHFR抑制作用。其他活性抗肿瘤化合物(19、41和47)的DHFR IC(50)值均高于15microM,表明它们可能通过其他作用方式发挥抗肿瘤作用。或者,这些化合物在哺